Non-muscle Invasive Bladder Cancer (NMIBC)
Oncology·MeSH: Non-Muscle Invasive Bladder Neoplasms
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| N-803 and BCG | ImmunityBio, Inc. (IBRX) |
Frequently asked questions
How many drugs are in development for Non-muscle Invasive Bladder Cancer (NMIBC)?
BioSniper tracks 1 drug in development for Non-muscle Invasive Bladder Cancer (NMIBC) across 1 company.
How many clinical trials target Non-muscle Invasive Bladder Cancer (NMIBC)?
There are 1 clinical trial targeting Non-muscle Invasive Bladder Cancer (NMIBC) tracked by BioSniper.
What is the prevalence of Non-muscle Invasive Bladder Cancer (NMIBC)?
The estimated prevalence of Non-muscle Invasive Bladder Cancer (NMIBC) is approximately 61.0 per 100,000 population.
Deep-dive into Non-muscle Invasive Bladder Cancer (NMIBC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis